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MYCN is the most powerful prognostic factor in cases of older children. However, how MYCN is related to the prognosis of infantile
cases is not clear. A mass screening program was carried out by measuring urinary catecholamine metabolites (VMA and HVA) from
6-month-old infants. Of 2084 cases detected by the screening program, MYCN amplification (MNA) was examined by Southern blot
analyses in 1533 cases from 1987 to 2000. Of the 1533 cases examined, 1500 (97.8%) showed no MNA, 20 cases (1.3%) showed
MNA from three to nine copies, and 13 (0.8%) cases showed more than 10 copies. The 4-year overall survival rates of these three
groups (99, 89 and 53%, respectively) were significantly different (Po0.001), indicating that MYCN copy number correlates with the
prognosis. Cases with MNA more than 10 copies were more advanced than those without amplification (stage III, IV vs I, II, IVs;
Po0.001). Patients with MNA more than 10 copies had significantly higher serum levels of neuron-specific-enolase (NSE) and ferritin
than non-amplified patients (P¼0.049, P¼0.025, respectively). MYCN amplification was strongly correlated with a poor prognosis in
infantile neuroblastoma cases. Therefore, for the selection of appropriate treatment, an accurate determination of MNA is
indispensable.
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Neuroblastoma (NB) is characterized by heterogeneous tumours,
some of which regress spontaneously while others proliferate and
progress (D’angio et al, 1971; Evans et al, 1971; Look et al, 1991).
The prognosis for NB in infants is much more favourable than it
is in older children. In 1973, the Mass Screening Program for
Neuroblastoma (MSPN) was commenced for the early detection of
NB in children living in Kyoto, Japan. A nationwide MSPN for
6-month-old infants began in 1985 (Sawada et al, 1984). The latter
MSPN revealed incidences of infantile NB in the early stages and
good biological prognostic factors of tumours increased (Hachitanda
et al, 1994; Sawada et al, 1998). However, it has been argued that
MSPN might result in the overdiagnosis of tumours, because some
of the tumours might spontaneously regress (Yamamoto et al,2 0 0 2 ;
Honjyo et al, 2003). And, the researcher has concluded that the
screening was ineffective, because clustered randomized trials have
not shown that screening led to a significant reduction in mortality
rate from NB (Woods et al, 2002; Kerbl et al, 2003). Consequently,
criticism has arisen that MSPN might detect only redundant
tumours with good prognostic factors. Actually, the prognosis in
most NB cases detected by MSPN has proved to be good. However,
some cases detected by MSPN have poor prognostic factors resulting
in relapsed disease (Kusafuka et al, 1995). Moreover, there are
reports that the good prognosis has been obtained by early
treatment in infantile NB cases with poor prognostic factors
(Kusafuka et al, 1995; Tanaka et al, 1998).
Although MYCN is well known to be the most powerful prog-
nostic factor in noninfantile cases of NB, how MYCN is related to
the prognosis of infantile cases, especially those discovered by
MSPN, is not clear. Therefore, we assessed MYCN amplification
(MNA) in infantile cases. If the prognoses of infantile NB cases
detected by mass screening and MNA correlate strongly, it is
necessary to evaluate MNA to decide on the appropriate treatment
for these cases.
PATIENTS AND METHODS
Analysis of urine catecholamine
Kits for screening children for urinary chatecholamines were
provided to the parents at public health centres throughout Japan
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swhen they brought their child in for a health checkup at 3 months
of age. Urine was collected by parents at home and sent to
screening centres by mail. Urine samples were assayed for vanillyl-
mandelic acid (VMA) and homovanillic acid (HVA) by high-
performance liquid chromatography (HPLC). When children’s
urinary levels of either VMA or HVA were 42.5 s.d. above normal,
the child was given clinical examinations for NB at a hospital.
The normal range was based on levels in healthy infants of an
age-matched (Sawada, 1988).
Patient population
Between April 1987 and March 2000, the population of the target
infants was 17139975. Of this number, 14496103 (84.6%) were
screened for elevated catecholamine levels. Of this number, 2084
children were diagnosed as having NB based on urinary catechol-
amine levels and were registered with the Committee of Neuro-
blastoma in the Japanese Society of Pediatric Oncology.
Staging The extent of the disease was evaluated according to the
Evans’s stage classification (Evans et al, 1971). The International
Staging System (INSS) (Brodeur et al, 1993) had not yet been
introduced when the MSPN began.
Biological features The prognosis and clinical features of these
cases were evaluated on the basis of the MNA. MYCN amplification
in tumour samples was detected using a Southern blot analysis
with MYCN second-exon probe according to standard procedures
(Brodeur et al, 1984). Although cases with 10 copies or more of the
MYCN gene are classified into the high-risk group in Japan
(Kaneko et al, 2002), in this study the MYCN gene was considered
amplified if there were more than three copies.
Registry
The hospitals reported the cases to the registration centre within 2
years of the findings of elevated catecholamine levels in the
screening process. The hospital reported the outcome of each case
5 years after the initial diagnosis of NB. However, the outcome of
the cases diagnosed between 1999 and 2000 has been 2 years since
the appearance of disease.
Statistical analysis
The Kaplan–Meier product limit method was used to estimate
the event-free survival (EFS) and overall survival (OS) from the
time of diagnosis of NB. The log-rank test was performed
to compare the OS probabilities between subgroups of patients.
The differences between dichotomous variables were analysed by
w
2 test when samples were of sufficient size. The two-tailed t-test
was carried out to compare the distributions of continuous
variables. A two-tailed P-value of o0.05 was considered to indicate
statistical significance.
RESULTS
Of 1533 infants with elevated urinary catecholamine levels that
were examined for MNA, 33 (2.2%) had tumours with MNA. Of
these 33 cases, 20 had MNA values from three to nine copies of the
MYCN gene (Table 1). Seventy-seven percent of cases with no
MNA had early stage (stages I, II and IVs) tumours. Thirteen cases
had more than 10 copies. Of these, only 30% had early stage
tumours. The cases without MNA had significantly higher
percentage of early stage tumours than cases with MNA over 10
copies (Po0.001) (Table 2).
Treatment and survival rates in patients with MNA
All of the 13 cases with MNA of more than 10 copies received
megatherapy with stem cell transplantation and radiotherapy. Six
of these cases died. None of 20 cases with MNA from three to nine
copies received the megatherapy with stem cell transplantation.
Sixteen of the 20 cases received mild chemotherapy, and four
cases received only surgical resection without chemotherapy. Only
two of the 20 cases died (Table 1). Case 15 had the unresectable
tumour of stage III and died of progressive disease although he
had received chemotherapy. Case 30 had the resectable tumour
with MYCN 3 copies by the Southern blot analysis and was not
classified into the high-risk group. At 3 months after the operation,
this patient had relapse with bone and bone marrow metastasis
and died of progressive disease. The primary tumour was judged
MYCN amplification by the FISH method that was performed after
the relapse.
Outcome
Of the 2084 cases that were detected NBs by the screening
programme, only 15 cases (0.7%) died within 5 years. OS was 99%.
Three-year EFS was 99% for cases without MNA (n¼1500), 88%
for cases with MNA from three to nine copies (n¼20), and 46%
for cases with MNA over 10 copies (n¼13) (Po0.001) (Figure 1).
The 4-year OS rate was 99% for cases without MNA, 89% for cases
with MNA from three to nine copies and 53% for cases with MNA
over 10 copies (Po0.001). In the cases with MNA over 10 copies,
all of the five cases except one died of progressive disease, though
they were received chemotherapy.
Characteristics of patients with and without MNA
Table 2 lists the clinical and biological characteristics of patients
with and without MNA. The cases with MNA (410 copies)
were found more frequently in advanced stages (stages III and IV),
than the cases without MNA (69 and 23%, respectively; Po0.001).
Of the cases with MNA (410 copies), a significantly higher
percentage of primary tumours was found in the adrenal glands
(92%) than in those without MNA (51%; P¼0.002). The patients
with MNA(410 copies) had significantly higher serum levels of
neuron-specific enolase (NSE) and ferritin than the patients with-
out MNA (P¼0.049, P¼0.025, respectively). Although the patients
with MNA (410 copies) had significantly higher urinary levels
of HVA than the patients without MNA (P¼0.008), there was no
difference in urinary levels of HVA (P¼0.985).
Characteristics of patients with MNA
The right side of Table 2 shows clinical and biological charac-
teristics of 33 cases with MNA more than three copies. Patients
in advanced stages (stage III and IV) had significantly poorer
prognoses (3-year EFS; 58.3%) than those in early stages (stage I,
II and IVs) (3-year EFS; 93.3%) (P¼0.021). The patients with
primary tumours found in the adrenal gland had significantly
poorer prognoses (3-year EFS; 68%) than those with the tumours
at other sites (3-year EFS; 100%) (P¼0.021). The group with high
serum levels of NSE also had a significantly poorer prognosis than
the group with low levels of NSE (P¼0.0005). However, urinary
levels of VMA and HVA, and serum levels of ferritin, did not
correlate with clinical outcomes (P¼0.364, 0.478 and 0.174,
respectively).
DISCUSSION
It is well known that the prognosis for NB in infants is good.
Indeed, the prognosis for NB detected by the Japanese MSPN was
excellent, with 98% survival. Although most of the cases detected
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sby the MSPN had biologically favourable factors, such as no-
deletion of 1p and low expression of the TRK-A gene, some
cases with unfavourable prognostic factors have been reported
(Matsunaga et al, 2000; Tajiri et al, 2001). MYCN is one of the most
important prognostic factors in NB (Rubie et al, 1997; Tonini et al,
1997). How MYCN is related to the prognosis and clinical features
of infantile cases, especially those discovered by MSPN, is not
clear. Our large-scale study clarified the frequency and clinical
features, including the prognoses, of the infantile NB cases with
MNA detected that were detected by MSPN.
Among 1533 cases discovered by the MSPN, 33 cases (2.2%)
showed MNA. This frequency is much lower than the 15–22%
frequency of MNA cases reported in the United States and Europe
(Tonini et al, 1997; Brodeur, 2003). In addition, in infants that were
less than 1-year-old, the frequency of MNA in our study was lower
than that reported in Italy (6.8%) (Tonini et al, 1997). This suggests
that the MSPN detected a greater number of tumours that sponta-
neously regressed and/or matured than did the clinical examinations.
MYCN is the powerful prognostic factor in infants whose NB was
discovered by the MSPN. The 3-year EFS rates (46%) and 4-year
OS rates (53%) for patients with MNA were significantly lower
than those for patients without MNA (99.3 and 99%, respectively)
(Po0.001). According to our previous investigation, the 4-year OS
rate for cases less than 12 months old with MNA of over 10 copies,
which include clinically detected cases, was 41% (Ikeda et al, 2002).
The prognosis of cases with MNA detected by MSPN might be
comparatively good though prognoses cannot be compared
because the researches the survival rates of cases detected clinically
and cases detected by MSPN did not investigated at the same time.
The infants with MNA that were detected by MSPN might be
considered to have benefited from the early detection provided by
the screening. Indeed, among patients with MNA, the 3-year EFS
rates (93.3%) of patients in stages I, II and IVs were significantly
higher than those in stages III and IV (58.3%). If these cases with
MNA were not discovered in the early stage by MSPN, some
malignant components of tumours would proliferate and progress.
As a result, the tumours would be discovered clinically after the
patients were 1-year-old. However, the number of cases with MNA
is only a very small proportion (2.2%) of the total cases discovered
by MSPN. In addition, it is clear that the number of NB patients
increased by introduction of MSPN. Therefore, the effectiveness of
MSPN discovery of patients with MNA is unclear.
Furthermore, tumours detected by MSPN might regress sponta-
neously (Yamamoto et al, 1998). Several institutions in Japan
recently adopted a conservative approach (the ‘wait and see’
approach), in which children discovered to have stage I, II or IVs
tumours by the MSPN were not given any therapeutic treatment in
the expectation that the tumour would spontaneously regress
(Yamamoto et al, 1998). However, a careful follow-up is necessary
in cases detected by MSPN, because some of the cases were found
to have MNA in the early stage. Most cases with MNA in this
study did not have higher urinary VMA levels than without MNA
and then, they were not predicted to have a poor clinical outcome
at their initial onset. Even in the early stages (stages I, II and IVs),
biopsies are required in order to determine the biological
prognostic factors of the tumour.
Moreover, in this study, it became clear that patients with MNA
of three to nine copies also had poor prognoses. MYCN gene has
Table 1 33 screened patients with MYCN amplification





1 150 3 CE VCR, CPM ( ) NED 0.8
2 4100 4 B VCR, CPM, VP-16, ADR, CDDP, DTI C ( ) Tumour death 0.3
w
3 55 4 CE CPM, VP-16, THP-ADR, CDDP, L-PAM,
CBDCA
( ) Auto-BMT NED 5.3
4 50 4 CE (+) (+) 25gy PBSCT Tumour death 2.3
w
5 50 4 CE (+) ( ) Tumour death 0.7
w




7 24 2 CE VCR, CPM, VP-16, THP-ADR, CDDP ( ) NED 5.9
8 20 2 CE CPM, VP-16, THP-ADR, CDDP (+) 20gy PBSCT Tumour death 2.7
w
9 15 4s CE (+) ( ) Auto-BMT NED 5.1
10 14 4 B CPM VP-16, THP-ADR CDDP-refuse (+) 12gy Tumour death 2.5
w
11 12 4 CE (+) ( ) CBSCT NED 2.0
12 10 3 CE VCR, CPM, CDDP, VP-16 (+) 10gy NED 3.30
13 10 4s CE CPM, VP16, THP-ADR, CDDP ( ) NED 4.7
14 6 4s CE CPM, VP16, THP-ADR, CDDP ( ) NED 5.0
15 5.7 3 B VCR, CPM, VP-16, THP-ADR, CDDP (+) 30gy Tumour death 0.9
w
16 5 2 CE VCR, CPM (+) 24gy NED 10.2
17 5 2 CE VCR, CPM, ADR, CDDP ( ) NED 8.1
18 4–5 4 CE VCR, CPM, THP-ADR, CDDP ( ) NED 8.8
19 4 1 CE VCR, CPM ( ) NED 6.6
20 4 1 CE VCR, CPM ( ) NED 8.7
21 4 1 CE VCR, CPM ( ) NED 6.1
22 4 3 PE CPM, VP-16, ADR, CDDP ( ) NED 7.5
23 3.7 4s CE VCR, CPM, ADR, CDDP ( ) NED 6.8
24 3 1 CE ( )(  ) NED 5.7
25 3 1 CE ( )(  ) NED 5.0
26 3 2 CE VCR, CPM, THP-ADR, CDDP ( ) NED 4.5
27 3 2 CE ( )(  ) NED 6.0
28 3 3 B CPM, VP-16, THP-ADR, CDDP ( ) NED 5.1
29 3 3 CE VCR, CPM, VP-16, THP-ADR, CDDP ( ) Auto-BMT NED 2.1
30 3 3 CE ( )(  ) Tumour death 0.9
w
31 3 4 CE CPM, THP-ADR, CDDP ( ) NED 8.7
32 3 4s CE (+) ( ) NED 7.8
33 2–4 4 B VCR, CPM, THP-ADR, CDDP ( ) NED 9.7
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sbeen analysed by the Southern blotting method for whole tumours,
but this method is not able to evaluate the status MNA in
individual NB cells. While, the FISH method is able to evaluate
MNA individual tumour cells, however, it is difficult to deter-
mine the copy number of MNA by the FISH method. MYCN
amplification was defined as a more than the fourfold increase
of MYCN signals in relation to the number of chromosomes 2 in
FISH method. Moreover, additional copies up to the fourfold were
defined as MYCN gain (Spitz et al, 2004). Spitz reported that 6% of
tumours displayed MYCN gain and this MYCN gain was associated
only with a poor outcome in localized or 4s NB cases (Spitz
et al, 2004). In our study, these patients with MNA of three to
nine copies might suggest the MYCN gain rather than MYCN
amplification. In cases 4 and 30, MNA were confirmed by FISH
method, however, in all the cases MNA were not confirmed by it.
MYCN amplification must be determined by adding the FISH
method in these cases (Mathew et al, 2001).
In the studies of the USA group (COG) and the German group, the
therapeutic strategy of surgical resection or observation is
recommended for NB patients in stages I or II, regardless of the
presence of MNA (Cohn et al, 1995; Kawa et al, 1999; Berthold and
Hero, 2000; Perez et al, 2000). However, in Japan, patients with MNA
of more than 10 copies are classified as being in a high-risk group. In
the protocol for high-risk NB, patients receive intensive chemo-
therapy combined with stem cell transplantation (Kawa et al,1 9 9 9 ;
Kaneko et al, 2002). Infantile NB patients with MNA as well as
patients in the high-risk group more than 1-year-old with MNA of
over 10 copies have been receiving intensive chemotherapy
(Matsumura and Michon, 2000). In our study 29 of 33 cases with
MNA received chemotherapy regardless of the stage. The use of
chemotherapy might improve the prognosis of patients with MNA.
In the cases with MNA over 10 copies, the treatment strategy
including more intensive chemotherapy might be necessary, because
five cases except one died of progressive disease. For cases with
Table 2 Characteristics of patients with and without MYCN amplification detected by mass screening for neuroblastoma
Number of cases (%)
MNA (410) MNA (3–9) MNA ( )
Patient characteristics (n¼13) (n¼20) (n¼1500) P-value MNA (+, 43) 3-yr EFS P-value
Tumour stage
I 0 (0) 5 (25) 595 (40) Po0.001
a, P¼0.05
b 100 P¼0.021
II 2 (15) 5 (25) 463 (31) (1,2,4s/3,4) 86 (1,2,4s/3,4)
III 2 (15) 5 (25) 280 (19) 71
IV 7 (54) 2 (10) 65 (4) 44
IVs 2 (15) 3 (15) 97 (6) 100
Gender
Female 3 (23) 11 (55) 722 (49) P¼0.043
a, P¼0.579
b 86
Male 11 (77) 9 (45) 764 (51) 68
Primary site
Adrenal gland 12 (92) 13 (65) 764 (51) P¼0.002
a, P¼0.131
b 68 P¼0.021
Other abdominal 0 (0) 3 (15) 456 (30) (adrenal gland/other site) 100 (adrenal gland/other site)
Chest 1 (8) 3 (15) 224 (15) 100
Pelvis 0 (0) 1 (5) 50 (3) 100
Neck 0 (0) 0 (0) 6 (0)
VMA
o20mgmgCr
 1 3 (23) 4 (20) 293 (20) 100
21–100mgmgCr
 1 7 (54) 15 (75) 982 (67) 82
4101mgmgCr
 1 2 (15) 1 (5) 184 (13) 75
(mean: 74.6mgmgCr
 1) (mean: 54.8mgmgCr







 1 0 (0) 2 (10) 206 (14) 100
21–100mgmgCr
 1 7 (54) 16 (80) 1084 (74) 78
4101ngmgCr
 1 6 (46) 2 (10) 170 (12) 63
(mean: 107.1mgmgCr
 1) (mean: 66.0mgmgCr






 1 5 (38) 9 (45) 526 (47) 93
16–100ngml
 1 2 (15) 7 (35) 568 (51) 89
4101ngml















 1 2 (15) 5 (25) 506 (54) 100
31–100ngml
 1 5 (38) 8 (40) 383 (41) 69
4101ngml













aP-value between MNA (410) and MNA ( ).
bP-value between MNA (3–9) and MNA ( ).
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sMNA, it is necessary to establish and perform the appropriate treat-
ment, including not only surgical resection but also chemotherapy.
MYCN amplification was strongly and inversely correlated with
the prognosis in infantile cases, although the frequency of MNA in
the cases discovered through the MSPN was small (2.2%).
Prediction of the presence of MNA in the tumour based on
urinary levels of HVA and VMA and stage of the tumour was
difficult in the cases we encountered. Our results demonstrate that
evaluation of MNA is important for the selection of appropriate
treatment for infantile NB.
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copies, and 53% for patients with more than 10 copies (Po0.001).
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